Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Prefilled Liquid Etanercept(Yisaipu) for Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-65，male or female~* Sign the informed consent~* Fulfill the 1966 AS New York criteria for axial spondyloarthritis(SpA)~* Active disease phase of SpA, defined as BASDAI≥4 or night back pain≥4 at screening~* Inadequate response to NSAID≥4 week~* Application of NSAID with stable dose for no less than 2 weeks at screening~* Stable dose of prenisone for at least four weeks at ≤10mg per day if used at screening, or stop oral use for at least 4 weeks or stop local injection at least 12 weeks~* Stable dose of any DMARD for at least four weeks if used at screening, or stop use for at least 4 weeks~* Stop and receiving washing out for at least 4 week if receiving Chinese traditional drug for AS, physical treatment, vaccication or IVIG~* Stop and receiving washing out for at least 12 week if receiving other biologics or other drug trials~* The lab exam should achieve the criteria as below~* Hb≥85g/L, 3.5×109/L≤WBC count≤10×109/L, PLT≥ lower limit of normal range, ALT≤2 fold of upper limit of normal range, serum creatine ≤upper limit of normal range. Negative pregnacy test for female patients. And promise to carry out contraception during the trial and 6 weeks after the trial is ended~Exclusion Criteria:~* Allergic condition or Allergic to IgG or any element of Yisaipu®~* Clinical or radiographic evidence of Complete ankylosis of spine~* Previous receiving TNF-a blockers therapy ≥3 months with poor response~* Achieve any following tuberculosis criteria~  1. History of active tubercolosis, or radiographic evidence of present or previous history of pulmonary tubercolosis~ 2. close contact with patients with tubercolosis, or with high risk of infection of tubercolosis such as immune suppression status~ 3. Strong positive of PPD skin test with diameter ≥10mm. at screen or within 3 weeks prior to screen~* Presence of acute infection or acute onset of chronic infection at screen~* Invasive fungal infection or conditional infection within 6 months prior to screen~* HBS-Ag or HBC-Ab positive at screen or history of HBS/HBC infection~* History of infection on artifitial joints~* Organ transplantation surgery within 6 months prior to screen~* Presence of other autoimmune diseases, including IBD, psoriasis, uveitis, SLE, multiple sclerosis, etc.~* History of congestive heart failure~* History of malignancies within 5 years prior to screen, excluding complete resection of squamous cell carcinoma, or basal cell carcinoma or cervical carcinoma in situ.~* AIDS or HIV infection~* History of lymphoma or lymphoproliferative disorders~* Presence of serious disorder of important organs or system~* Presence of factors which may influence the compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- group I (Type: EXPERIMENTAL): twice weekly 25 mg prefilled liquid etanercept
- group II (Type: EXPERIMENTAL): once weekly 50 mg prefilled liquid etanercept
- group III (Type: ACTIVE_COMPARATOR): 25 mg twice weekly lyophilized etanercept powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete